/ /

Mark Fuerst
HCV-related liver disease on the rise in women
The benefits of HCV treatment will need to extend to all patients in order to stem the rising tide of HCV complications among women and men.
Study: HCV week 4 viral load predicts DAA treatment response
Week 4 HCV RNA levels have implications for treatment with direct-acting antiviral agents for hepatitis C virus infections.
Researchers: Hepatitis C virus control needs a public health approach
A new study suggests a public health approach is necessary to control the spread of hepatitis C virus in urban communities.
DAAs safely treat chronic kidney disease in HCV patients
Direct-acting antiviral therapy with sofosbuvir-based combinations safely and effectively treats HCV infection in patients with early-stage chronic kidney disease.
Primary care can manage hep C infections with DAAs
Primary care professionals can “substantially expand” HCV treatment in the community, according to new research.
DAAs improve patient and graft survival after liver transplant
Liver transplant outcomes have improved following the introduction of new hepatitis C virus drugs, according to a new study.
Direct-acting antivirals reduce liver cancer risk
A sustained response to direct-acting antivirals lowers the risk of hepatocellular carcinoma, a new study finds.
Report highlights critical actions needed to monitor HCV epidemic
A new report highlights key missing elements needed to achieve complete elimination of hepatitis C virus.
Sofosbuvir reduces transplant rate in HCV patients
Sofosbuvir-based therapy successfully treats HCV patients with decompensated liver disease, according to a new study.
Direct-acting antivirals prevent liver cancer recurrence
New research finds direct-acting antivirals can be given safely to those on liver transplant waitlist.